Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 Months' experience

Blood

Volumn 100, Issue 2, 2002, Pages 435-441

  Braziel, Rita M ^a,b   Launder, Teresa M ^a,b   Druker, Brian J ^a,b   Olson, Susan B ^a,b   Magenis, R Ellen ^a,b   Mauro, Michael J ^a,b   Sawyers, Charles L ^a,b   Paquette, Ronald L ^a,b   O'Dwyer, Michael E ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; RECOMBINANT ALPHA INTERFERON;

ADULT; AGED; ARTICLE; BLOOD DISEASE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; CYTOKINE PRODUCTION; CYTOPENIA; DOSE RESPONSE; DOSE TIME EFFECT RELATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PATHOPHYSIOLOGY; PERIPHERAL CIRCULATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; REMISSION;

EID: 0037100308     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.2.435     Document Type: Article

References (14)

1. The molecular biology of chronic myeloid leukemia
2. Regulated expression of p210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate
3. Effects of a selective inhibitor of the Abl tyrosine kinase on growth of BCR-ABL positive cells
4. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
5. Inhibition of the Abl kinase activity blocks the proliferation of BCR-ABL+ leukemic cells and induces apoptosis
6. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
7. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro
8. Chronic myelogenous leukemia and the chronic myeloproliferative disorders
9. Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia: Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features
10. Histopathological changes in bone marrow biopsies from patients with chronic myeloid leukaemia after treatment with recombinant alpha-interferon
11. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
12. BCR/ABL gene amplification: A possible mechanism of drug resistance in patients treated with an ABL-specific kinase inhibitor
13. Relapse in Ph+ leukemia patients treated with an Abl-specific kinase inhibitor is associated with reactivation of BCR-ABL
14. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification